Revenue segments as reported by the company.

U.S. Healthcare Solutions

International Healthcare Solutions

Pharmaceutical Distribution Services

Other

Intersegment eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, and administrative

Depreciation and amortization

Employee severance, litigation, and other

Goodwill impairment

Impairment of assets

Acquisition, integration, and restructuring expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cencora Inc

CoreSite Realty Corporation owns, develops, and operates data centers in certain data center markets in the United States, including Los Angeles, the San Francisco Bay and Northern Virginia areas, Chicago, and New York City. Its customer base consists of enterprise customers, communications service providers, media and content companies, government agencies, and educational institutions.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Cencora Inc (COR) excels in Q3, eyes growth through strategic partnerships

Cencora's Q3 performance reflects strong growth and strategic positioning in the healthcare industry. Leveraging its leadership in specialty services, the company aims to capitalize on opportunities through partnerships and customer-centric strategies while addressing challenges in managing key financial factors.

Cencora Inc posts robust fiscal 2024 results, eyes strategic expansion

Cencora Inc's Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and concerns about future challenges. The company's focus on expanding into new specialties and managing potential headwinds demonstrates a proactive approach to growth and risk management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Offi.

Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cencora (COR) is a Top-Ranked Momentum Stock: Should You Buy?

Agilent Technologies

AbbVie

Accenture Plc

AGCO

Applied Materials

Amgen

Cboe Global Markets

Coterra Energy

Microchip Technology

Microsoft

Raymond James

RenaissanceRe Hlds

Steel Dynamics

TFI International

Unum

Visa

Vistra Energy

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable options income strategy. In this monthly series, we present how to go about selecting the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options, CALL options, and deep-in-the-money CALL options.

Earn Double-Digit Income With Options (October 2023)

Automatic Data Processing

Broadridge Financial

Brown & Brown

Costco

Cintas Corp

Healthcare Realty Trust Inc

Rollins

SPDR S&P 500 ETF Trust

Tractor Supply

UnitedHealth Group

In this monthly series, I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To rank stocks, I do a quality assessment and sort stocks by quality scores, breaking ties with additional metrics. This month, I'm presenting stocks with A+ Dividend Quality Grades and strictly increasing dividends, earnings, and revenue over the past decade.

10 Dividend Growth Stocks For September 2023

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Retain Cencora (COR) Stock for Now

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why AmerisourceBergen (COR) is a Top Value Stock for the Long-Term

Why AmerisourceBergen (COR) is a Top Growth Stock for the Long-Term

AmerisourceBergen

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care.

AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care

The stock price of CoreSite Realty Corp (NYSE: COR) increased by over 8% pre-market today. This is why it happened.

CoreSite Realty (COR) Stock: Why The Price Jumped Today

News for Cencora Inc Stock (COR)